Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study

Fig. 2

Breast cancer-specific survival proportions, hazard rates and adjusted hazard ratios by IHC subtype and pTN. Legend: Survival proportions (panels a–f), hazard rates (panels g–l) and adjusted hazard ratios (panels m–r) including n = 16,809 women with known information on ER, PR, HER2, grade, TNM stage and surgery type, and restricted to T1-2, N any, M0. Numbers at risk at start: ER+PR+HER2− n = 6229 (pT1pN0), n = 1362 (pT2pN0), n = 3125 (pT1-2pN+); ER+PR−HER2− n = 1309 (pT1pN0), n = 361 (pT2pN0), n = 694 (pT1-2pN+); ER+PR+HER2+ n = 437 (pT1pN0), n = 171 (pT2pN0), n = 380 (pT1-2pN+); ER+PR−HER2+ n = 225 (pT1pN0), n = 92 (pT2pN0), n = 230 (pT1-2pN+); HER2pos n = 250 (pT1pN0), n = 131 (pT2pN0), n = 310 (pT1-2pN+); TNBC n = 638 (pT1pN0), n = 413 (pT2pN0), n = 452 (pT1-2pN+). Logrank tests of survival differences by grade: ER+PR+HER2− p < 0.001, ER+PR−HER2− p < 0.001, ER+PR+HER2+ p = 0.0001, ER+PR−HER2+ p = 0.6100, HER2pos p = 0.0099, TNBC p < 0.001. Hazard rate curves only plotted until the last event in each group. Hazard ratios adjusted for age and year at diagnosis, subtype × pTN interaction, grade, surgery type and follow-up. N = 16,809. Estimates of HRs are given in Additional file 9

Back to article page